검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ciprofloxacin (ciprofloxacin) Laboratorios Sophia S.A de C.V.·Brain and Central Nervous System T… ORR 6%·t½ 2.52 h |
|---|---|
Overview Program | ciprofloxacin |
Overview Company | Laboratorios Sophia S.A de C.V. |
Overview Modality | CGT |
Overview Target | Brain and Central Nervous System Tumors |
Overview Indication | Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
PK/PD Half-life | 2.52 h |
PK/PD Species | Rabbit |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rabbit |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Restoring ciprofloxacin efficacy via β-caryophyllene synergy for concurrent infection control and tissue regeneration.. The occurrence of antimicrobial-resistant microbial infection on the wounds are considered a critical issue in delayed or non-healing wounds. Due to the scarcity of new antibiotics in the market, alternate combinational therapies are gaining interest in tackling this issue.… |
Clinical Primary efficacy | ORR 6% |
Clinical ORR | 15% |
Clinical PFS | 4.7 |
Clinical OS | 11.2 |
Clinical Result source | ClinicalTrials.gov NCT00332163 |
Clinical Data Tier / Score | A · 20 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ciprofloxacin (ciprofloxacin) Laboratorios Sophia S.A de C.V.·Brain and Central Nervous System T… ORR 6%·t½ 2.52 h |
|---|---|
Overview Program | ciprofloxacin |
Overview Company | Laboratorios Sophia S.A de C.V. |
Overview Modality | CGT |
Overview Target | Brain and Central Nervous System Tumors |
Overview Indication | Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
PK/PD Half-life | 2.52 h |
PK/PD Species | Rabbit |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rabbit |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Restoring ciprofloxacin efficacy via β-caryophyllene synergy for concurrent infection control and tissue regeneration.. The occurrence of antimicrobial-resistant microbial infection on the wounds are considered a critical issue in delayed or non-healing wounds. Due to the scarcity of new antibiotics in the market, alternate combinational therapies are gaining interest in tackling this issue.… |
Clinical Primary efficacy | ORR 6% |
Clinical ORR | 15% |
Clinical PFS | 4.7 |
Clinical OS | 11.2 |
Clinical Result source | ClinicalTrials.gov NCT00332163 |
Clinical Data Tier / Score | A · 20 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교